Clinical & Scientific

Backed by dialysis giants DaVita and U.S. Renal Care, a new startup licenses a first-in-class therapy to transform treatment for kidney patients.

UK biotech Alchemab hires Sanofi's Ulrich Wendt as CBO to forge major pharma deals for its novel AI platform that mines the secrets of human resilience.

A new biotech firm unveils a first-in-class cancer drug targeting E6AP, aiming to restore the body's natural defenses against HPV-positive head and neck cancer.

A new alliance aims to overhaul Alzheimer's research, demanding a precision approach for the 65% of patients carrying the high-risk APOE4 gene.

A partnership between Biophytis and LynxKite leverages AI to fast-track therapies for sarcopenia and macular degeneration, backed by Singapore's RIE 2030 plan.

The German biotech firm secured its Nasdaq listing, but a near-total investor redemption leaves its cancer-drug pipeline with less than $1M in trust funds.

Pierre Fabre's Avène brand is using AI to sextuple its clinical trial size for a new acne treatment, signaling a new era for dermo-cosmetic research.

Psyence BioMed is building a pharmaceutical powerhouse by controlling its supply chain, a strategic move that could redefine the future of psychedelic medicine.

Vitestro raises $70M from Labcorp and Mayo Clinic to deploy its AI-powered blood-drawing robot, addressing global phlebotomist shortages and care quality.

New analysis of Phase 1 data for NKGen Biotech’s troculeucel suggests cognitive benefits, offering a potential new weapon against neuroinflammation.

In the quest to drug the 'undruggable,' Erasca consolidates worldwide control of its promising pan-RAS inhibitor, setting the stage for a global showdown.

As Hyperfine preps its 2025 results, investors and clinicians watch to see if its portable Swoop MRI can translate clinical promise into financial success.

A new multi-year deal gives RNAi leader Alnylam access to Helix's vast genomic and clinical data, aiming to redefine the speed of drug discovery.

BioRestorative Therapies is leveraging its clinical-grade regenerative medicine to disrupt the aesthetics industry. Can science beat marketing?

AI drug discovery firm Proxima appoints three titans of science to its board, signaling a major push in proximity therapeutics to rewrite medicine's rules.

With a total of $160M in Series B funding, Atavistik Bio is advancing its selective allosteric inhibitors for rare diseases HHT and MPNs.

A new growth medium aims to standardize stem cell production, addressing key regulatory and scalability challenges in the booming regenerative medicine market.

A new partnership aims to use light and AI to break bottlenecks in drug development, promising to make personalized medicine faster and more accessible.

A landmark Japan-international partnership aims to break down barriers and accelerate revolutionary stem cell treatments for patients worldwide.

MAIA Biotechnology secured a crucial $30M to advance its promising lung cancer drug, but the move sent its stock plunging amid investor fears of dilution.